Multiple Sclerosis Clinical Trial
— SPA-SEPOfficial title:
Thermal Cures in the Treatment of Multiple Sclerosis: Effectiveness on the Quality of Life
Multiple Sclerosis (MS) is a chronic, progressive disease with a high prevalence in France, with significant public health consequences. The benefit of spa treatments on the quality of life in this population has not been evaluated. The methods of study in clinical pharmacology can be a scientific methodological model for the evaluation of thermal practices and it is in this perspective that investigators want to lead this project.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | August 2021 |
Est. primary completion date | May 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patient with primary or progressive secondary-phase MS - Showing EDSS <7 severity criteria - Patient with MS for whom an indication of spa treatment has been made, - Patient agreeing to participate in this study and therefore accepting the constraints related to the design "immediate cure-deferred cure", - Patient receiving the general social security scheme, - Patient having given written consent to participate in the study Exclusion Criteria: - Patient does not meet the inclusion criteria, - Patient with relapsing remitting MS - Patient unfit according to the investigator to complete the rating scales - Patient with heat intolerance called "Uhthoff effect" - Patient with a contraindication to the spa treatment: urinary or faecal leakage, wound, thrombophlebitis less than three months old, unstabilized cardio respiratory disease. - Patient with serious life-threatening condition (ie, cancer) - Patient under tutorship or curatorship - Patient participating in another interventional clinical research project |
Country | Name | City | State |
---|---|---|---|
France | Département de Médecine Physique et de Réadaptation, Hopital LAPEYRONIE | Montpellier |
Lead Sponsor | Collaborator |
---|---|
Association Francaise pour la Recherche Thermale |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Benefit of spa treatment on quality of life assessed by the scale SEP-59 | Difference of the score of quality of live assessed by the scale SEP-59 between the patient will receive the immediat spa therapy and the second group which won't receive the spa therapy immediately. SEP-59 is built on the basis of a generic scale, the SF-36. The analysis of SEP-59 is done by computer processing in order to calculate the score of the various axes (pain, physical activity, general wellbeing ...) which are independent (there is no overall score). | within 15 weeks after inclusion | |
Secondary | Benefit of a spa treatment based on average number of steps per day for one week assessed by actimeter | Difference of the average number of steps per day for one week between the patient will receive the immediat spa therapy and the second group which won't receive the spa therapy immediately. | 9 weeks after inclusion | |
Secondary | Benefit of a thermal cure based on treatment consumption of hospital and ambulatory care | Difference of the number of treatment consumption of hospital and ambulatory care between the patient will receive the immediat spa therapy and the second group which won't receive the spa therapy immediately | 15 to 17 weeks after inclusion | |
Secondary | Benefit of a thermal cure based on depression and anxiety assessed by the scale Hospital Anxiety and depression scale | Difference of the level of pain assessed by the scale Hospital Anxiety and depression between the patient will receive the immediat spa therapy and the second group which won't receive the spa therapy immediately.HADS is a self-administered scale of 14 items, divided into 2 subscales of 7 items (Anxiety or HADS-A, Depression or HADS-D). It contains no somatic item that can be confused with symptomatic manifestations of a disease. Each item is scored on a scale of 0 to 3. A score is generated for each of the two sub-scales and for the entire HADS (HADS-T). Limit scores distinguish between: non-cases or asymptomatic cases (score = 7); probable or borderline cases (score 8-10); clearly or clinically symptomatic cases (score = 11). |
15 to 17 weeks after inclusion | |
Secondary | Benefit of a thermal cure based on tiredness assesed by the fatigue impact scale | Difference of the level of pain assessed by the fatigue impact scale between the patient will receive the immediat spa therapy and the second group which won't receive the spa therapy immediately. It is a self-assessment tool in which the patient is asked to note the extent to which fatigue has caused them problems in certain situations. (0 = no problem, 4 = extreme problems). A maximum score of 160 is obtained for the 40 items. | 15 to 17 weeks after inclusion | |
Secondary | Benefit of a thermal cure regarding pain assessed by the scale DN 4 | Difference of the level of pain assessed by the DN4 scale between the patient will receive the immediat spa therapy and the second group which won't receive the spa therapy immediately | 15 to 17 weeks after inclusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT02845635 -
MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
|